Lifestyle
- Regular aerobic exercise
- Weight management
- Smoking cessation
Low-Density Lipoprotein · LDL-C · LDL
LDL-C quantifies the amount of low-density lipoprotein cholesterol in the blood, which transports cholesterol to cells.
Fasting is required for accurate measurement; ranges may vary slightly by lab.
Low-Density Lipoprotein Cholesterol (LDL-C) is a type of lipoprotein responsible for transporting cholesterol to cells throughout the body. Biologically, LDL-C is a critical component of cell membranes and a precursor for steroid hormones and bile acids. It is often referred to as 'bad cholesterol' due to its association with atherosclerosis when present in excess. Clinically, elevated LDL-C levels are a well-established risk factor for cardiovascular diseases (CVD), including coronary artery disease (CAD), peripheral vascular disease (PAD), and cerebrovascular disease (CCVD). Researchers have found that high LDL-C levels contribute to the formation of atherosclerotic plaques, which can lead to major adverse cardiovascular events (MACEs). For athletes and biohackers, maintaining optimal LDL-C levels is crucial for cardiovascular health and longevity. While LDL-C is not directly linked to athletic performance, its management is essential for reducing the risk of cardiovascular complications that could impair long-term health. Researchers observed that LDL-C levels can be influenced by factors such as diet, exercise, and genetic predisposition. Caveats in measuring LDL-C include the need for fasting prior to testing, as recent food intake can affect lipid levels. Additionally, LDL-C measurements can be confounded by the presence of lipoprotein(a), which may require correction for accurate assessment. Time of day does not significantly affect LDL-C levels, but consistent testing conditions are recommended for reliable monitoring.
Klinische Bedeutung
Elevated LDL-C levels indicate an increased risk of atherosclerosis and cardiovascular diseases. Lowered LDL-C levels are generally associated with reduced cardiovascular risk.
Progressively rising LDL-C levels suggest increased cardiovascular risk; re-test in 4-6 weeks if outside optimal range.
Progressively falling LDL-C levels indicate reduced cardiovascular risk, often due to lifestyle or medication interventions.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if on cholesterol-lowering medications.
Testing Frequency
Annually for healthy adults, more frequently if at risk for CVD
Directly measures
Current research suggests that while LDL-C is a well-established biomarker for cardiovascular risk, optimal target levels and reference ranges remain debated, particularly in populations with elevated lipoprotein(a). Researchers have not yet established the precise role of LDL-C in the context of post-stroke cognitive impairment, highlighting a gap in understanding its predictive value in this setting. Additionally, clinical questions remain regarding the synergistic effects of LDL-C with other biomarkers like Lp(a) and hs-CRP on cardiovascular event risk.
890
Total Citations
11
Human/RCT
5.7
Avg. Influence
2025
Latest
This review discussed the triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a potential risk marker for metabolic syndrome and cardiovascular disease. Researchers found that increased plasma triglycerides and decreased HDL-C levels are associated with these conditions, suggesting that the TG/HDL-C ratio may be a valuable predictor of cardiovascular risk.
This review examined the significance of apolipoprotein B (apoB) as a biomarker for cardiovascular disease. Researchers found that apoB levels provide a more accurate measure of atherogenic lipoproteins compared to low-density lipoprotein cholesterol (LDL-C). The review discusses the ongoing debate regarding the use of apoB in clinical guidelines for cardiovascular risk assessment.
This systematic review and meta-analysis evaluated blood biomarkers related to post-stroke cognitive impairment (PSCI). Researchers found that levels of homocysteine, C-reactive protein, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) were significantly higher in PSCI patients compared to those without cognitive impairment. The study suggests these biomarkers could serve as effective indicators for PSCI.
This article discussed a new approach to obesity treatment focusing on weight loss as a means to prevent complications. Researchers highlighted the importance of managing low-density lipoprotein cholesterol (LDL-C) levels as a biomarker in this context, emphasizing that effective weight loss can lead to improved health outcomes.
This study investigated the relationship between low-density lipoprotein cholesterol (LDL-C) levels and bone mineral density (BMD) in adults aged 20 to 59. Researchers found a negative association between LDL-C and lumbar BMD, indicating that higher LDL-C levels may be linked to lower bone density. The study suggests that LDL-C could serve as a biomarker for early osteoporosis detection.
This narrative review examined the lipid abnormalities associated with hypothyroidism. Researchers found that elevated thyroid-stimulating hormone (TSH) levels correlate with increased low-density lipoprotein cholesterol (LDL-C) levels, and thyroid hormone treatment can reverse these lipid abnormalities, potentially improving cardiovascular outcomes.
This study examined the effects of pelacarsen on low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) cholesterol (Lp(a)-C) in patients with cardiovascular disease. Researchers found that pelacarsen significantly lowered Lp(a)-C levels and had a neutral to mild lowering effect on LDL-C corrected for Lp(a)-C content. The study suggests that LDL-C corrected for Lp(a) provides a more accurate reflection of changes in LDL-C than traditional laboratory-reported LDL-C.
This review focused on recombinant high-density lipoprotein formulations as potential therapies for cardiovascular disease. Researchers noted that low-density lipoprotein cholesterol (LDL-C) lowering therapies have limited effectiveness in raising HDL-C levels. The study emphasizes the need for further clinical trials to evaluate the efficacy of novel HDL-modifying therapies.
This review highlighted the clinical significance of electronegative low-density lipoprotein (L5 LDL) cholesterol in atherothrombosis. Researchers found that elevated L5 LDL levels correlate with the severity of cardiovascular diseases. The study proposes that L5 LDL could be a promising biomarker for assessing cardiovascular risk and guiding treatment decisions.
This article focused on lipoprotein(a) as an independent risk factor for cardiovascular disease. Researchers noted that despite effective LDL-C lowering therapies, elevated lipoprotein(a) remains a significant risk factor, indicating the need for targeted strategies to reduce its levels.
Research publications about LDL-Cholesterin over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer